HC Wainwright & Co. Maintains Buy on Regenxbio, Lowers Price Target to $21

Benzinga Newsdesk www.benzinga.com Negative 75.4%

Neg 75.4% Neu 0% Pos 0%

HC Wainwright & Co. analyst Yi Chen maintains Regenxbio (NASDAQ:RGNX) with a Buy and lowers the price target from $23 to $21.